Top

Published in:

01-08-2011 | Epilepsy

Treatment of Epilepsy to Optimize Bone Health

Author: Alison M. Pack, MD, MPH

Published in: Current Treatment Options in Neurology | Issue 4/2011

Opinion statement

When treating a person with epilepsy, one must consider many factors in addition to the obvious need to treat the seizures. Both epilepsy itself and treatment with antiepileptic drugs (AEDs) subject one to numerous potential secondary long-term health concerns. Poor bone health is one of these concerns. Studies suggest that persons with epilepsy treated with AEDs have an increased risk of fracture, low bone mineral density (BMD), and abnormalities in bone metabolism. Multiple factors likely contribute to the increased risk. Falls during generalized tonic-clonic seizures, secondary effects of AEDs on balance, inactivity, low BMD, reduced calcium intake, reduced active vitamin D metabolites, and a genetic predisposition to low BMD may all contribute. Studies suggest a differential influence of AEDs. Phenytoin, phenobarbital, and primidone are most consistently associated with a negative impact on bone. Carbamazepine and valproate may also result in bone abnormalities, but data are mixed. Current studies suggest that lamotrigine has limited (if any) effect, but again, data are inconsistent. Other AEDs have received limited study. Screening for poor bone health includes serologic testing of vitamin D metabolites (notably 25-hydroxyvitamin D) as well as BMD testing using dual energy x-ray absorptiometry. Optimizing intake of calcium and vitamin D is important for all persons with epilepsy treated with AEDs. Although many treatments for low BMD are available, these agents have not been studied in persons with epilepsy treated with AEDs. Overall, physicians treating persons with epilepsy must consider the potential effect of having epilepsy and its main treatment, AED therapy, on bone health. For patients in whom bone health is a particular concern (eg, those with diagnosed bone disease or with significant risk factors for bone disease, including glucocorticosteroid use), it is best to avoid AEDs known to negatively affect bone. In addition, practitioners should work with other treating physicians to optimize bone health in these patients.

Pack A. Bone health in people with epilepsy: Is it impaired and what are the risk factors? Seizure. 2008;17(2):18.CrossRef

Souverein PC, Webb DJ, Petri H, et al. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia. 2005;46(2):304–10.PubMedCrossRef

3.•

Petty SJ, Hill KD, Haber NE, et al. Balance impairment in chronic antiepileptic drug users: a twin and sibling study. Epilepsia 2010, 51(2):280–8. PubMedCrossRef

Vestergaard P. Epilepsy, osteoporosis and fracture risk—a meta-analysis. Acta Neurol Scand. 2005;112(5):277–86.PubMedCrossRef

Pack AM, Walczak TS. Bone health in women with epilepsy: clinical features and potential mechanisms. Int Rev Neurobiol. 2008;83:305–28.PubMedCrossRef

Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia. 2002;43(7):768–72.PubMedCrossRef

Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology. 2006;66(9):1318–24.PubMedCrossRef

Tsiropoulos I, Andersen M, Nymark T, et al. Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. Epilepsia. 2008;49(12):2092–9.PubMedCrossRef

Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia. 2004;45(11):1330–7.PubMedCrossRef

10.

Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug–induced bone loss in young male patients who have seizures. Arch Neurol. 2002;59(5):781–6.PubMedCrossRef

11.

Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 2002;58(9):1348–53.PubMed

12.

Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology. 2001;57(3):445–9.PubMed

13.

Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr. 1995;127(2):256–62.PubMedCrossRef

14.

Sheth RD, Binkley N, Hermann BP. Gender differences in bone mineral density in epilepsy. Epilepsia. 2008;49(1):125–31.PubMedCrossRef

15.

Samaniego EA, Sheth RD. Bone consequences of epilepsy and antiepileptic medications. Semin Pediatr Neurol. 2007;14(4):196–200.PubMedCrossRef

16.

Coppola G, Fortunato D, Auricchio G, et al. Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia. 2009;50(9):2140–6.PubMedCrossRef

17.

Sheth RD, Binkley N, Hermann BP. Progressive bone deficit in epilepsy. Neurology. 2008;70(3):170–6.PubMedCrossRef

18.

Henderson RC, Lark RK, Gurka MJ, et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics. 2002;110(1 Pt 1):e5.PubMedCrossRef

19.

Menon B, Harinarayan CV. The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism–a longitudinal study. Seizure. 2010;19(3):153–8.PubMedCrossRef

20.

Rauchenzauner M, Griesmacher A, Tatarczyk T, et al. Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children. Dev Med Child Neurol. 2010;52(3):283–8.PubMedCrossRef

21.

Nettekoven S, Ströhle A, Trunz B, et al. Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur J Pediatr. 2008;167(12):1369–77.PubMedCrossRef

22.

Szulc P, Delmas PD. Biochemical markers of bone turnover in osteoporosis. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. New York: Lippincott Williams & Williams; 2009. p. 174–9.

23.

Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology. 2008;70(18):1586–93.PubMedCrossRef

24.

Sowers M, Crutchfield M, Bandekar R, et al. Bone mineral density and its change in pre- and perimenopausal white women: the Michigan Bone Health Study. J Miner Res. 1998;13(7):1134–40.CrossRef

25.

Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology. 2004;62(11):2051–7.PubMed

26.

Verrotti A, Greco R, Morgese G, Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol. 2000;47(3):385–8.PubMedCrossRef

27.

Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia. 2002;43(12):1488–92.PubMedCrossRef

28.

Kim SH, Lee JW, Choi KG, Chung HW, Lee HW. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy and Behavior. 2007;10(2):291–5.PubMedCrossRef

29.

Mintzer S, Boppana P, Toguri J, et al. Vitamin D levels and bone turnover in epilepsy taking carbamazepine or oxcarbazepine. Epilepsia. 2006;47(3):510–5.PubMedCrossRef

30.

Cansu A, Yesilkaya E, Serdaroğlu A, et al. Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol. 2008;39(4):266–71.PubMedCrossRef

31.

Gou CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia. 2001;42(9):1141–7.

32.

Verrotti A, Agostinelli S, Coppola G, Parisi P, Chiarelli F. A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy. Eur J Neurol. 2010;17(2):232–7.PubMedCrossRef

33.•

Ensrud KE, Walczak TS, Blackwell TL, et al. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008, 71(10):723–30.PubMedCrossRef

34.

Sheth RD, Hermann BP. Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr Neurol. 2007;37(4):250–4.PubMedCrossRef

35.

Pierce Jr WM, Nardin GF, Fuqua MF, et al. Effect of chronic carbonic anhydrase inhibitor therapy on bone and mineral density in white women. J Bone Miner Res. 1991;6(4):347–54.PubMedCrossRef

36.

Nissen-Meyer LS, Svalheim S, Tauboll E, et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia. 2007;48(10):1–11.CrossRef

37.

Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-enhanced CYP 24 expression in drug-induced osteomalacia. J Clin Invest. 2005;115(1):177–86.PubMed

38.

Zhou C, Assem M, Tay JC, et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest. 2006;116(6):1703–12.PubMedCrossRef

39.

Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol. 2005;57(2):781–6.CrossRef

40.

Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure. 1999;8(6):339–42.PubMedCrossRef

41.

Bhatt R, Bhatt S, Hameed M, Rameshwar P, Siegel A. Amygdaloid kindled seizures can induce functional and pathological changes in thymus of rat: role of the sympathetic nervous system. Neurobiol Dis. 2006;21(1):127–37.PubMedCrossRef

42.•

Lambrinoudaki I, Kaparos G, Armeni E, et al. BsmI vitamin D receptor’s polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy. Eur J Neurol 2011;18(1):93–8.PubMedCrossRef

43.

Pack AM. Genetic variation may clarify the relationship between epilepsy, antiepileptic drugs, and bone health. Eur J Neurol. 2011;18(1):3–4.PubMedCrossRef

44.

Thakkinstian A, D’Este C, Eisman J, Nguyen T, Attia J. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J Bone Miner Res. 2004;19:419–28.PubMedCrossRef

45.

FRAX®: WHO risk factor tool. Available at: http://www.sheffield.ac.uk/FRAX/. Accessed April 8, 2011.

46.

Mikati MA, Dib L, Yamout B, et al. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology. 2006;67(11):2005–14.PubMedCrossRef

47.

IOM (Institute of Medicine). 2011. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press. Available at: http://www.iom.edu/vitamind. Accessed April 8, 2011.

Title: Treatment of Epilepsy to Optimize Bone Health
Author: Alison M. Pack, MD, MPH
Publication date: 01-08-2011
Publisher: Current Science Inc.
Published in: Current Treatment Options in Neurology / Issue 4/2011
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-011-0133-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treatment of Epilepsy to Optimize Bone Health

Opinion statement

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 4/2011

Treatment of Depression in Patients with Epilepsy

Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update

Medical Management of Patients With Brain Tumors

Treatment and Prophylaxis of Hematologic Malignancy in the Central Nervous System

Seizure Management in the Setting of Hepatic Disease

Treatment Options in Juvenile Myoclonic Epilepsy